A Phase 2 Study of ABSK043 Combined With Osimertinib
Starting soon · Phase 2
Conditions studied: Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
In brief
This is a phase 2, open-Label study to evaluate the efficacy and safety of ABSK043 Combined with Osimertinib in participants with EGFR-Mutated locally advanced or metastatic Non-Small Cell Lung Cancer
Key facts
- Study ID
- NCT07710612
- Run by
- Abbisko Therapeutics Co, Ltd
- People needed
- 72
- Starts
- 2026-08-31
- Expected to finish
- 2030-12-31
- Last updated by the study team
- 2026-07-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may not qualify if…
- 1. Histological or cytological examinations suggest that NSCLC squamous cells is the predominant histology, or contains small cell lung cancer, neuroendocrine carcinoma, etc.
- Has a history of interstitial lung disease (ILD)/pneumonitis or active ILD 3. Spinal cord compression and unstable brain metastases. 4.Any unresolved toxicities from prior systemic therapy greater than CTCAE v6.0 Grade 1 at the time of starting study treatment.
- Participants with obvious and unstable pleural effusion, peritoneal effusion or pericardial effusion .
- Has a history of other malignant tumors, or currently have other malignant tumors.
- Participants with known HIV infection.
Where it is running
- The First Affiliated Hospital, Sun Yat-sen University — Guangzhou, Guangdong, China
- Harbin Medical University Cancer Hospital — Harbin, Heilongjiang, China
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, Hubei, China
- The First Hospital of China Medical University — Shenyang, Liaoning, China
- Shanghai Chest Hospital — Shanghai, Shanghai Municipality, China
- Shanxi Provincial Cancer Hospital — Taiyuan, Shanxi, China
- The First Affiliated Hospital, Zhejiang University School of Medicine — Hangzhou, China
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.